Search Results for "magnesium hydroxide"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for magnesium hydroxide. Results 1 to 10 of 11 total matches.
In Brief: Only The Name Remains The Same
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010 (Issue 1341)
Ingredients
Mylanta Classic Liquid Aluminum hydroxide,
Maximum Strength, magnesium hydroxide,
Regular ...
A Medical Letter subscriber was surprised to discover that a new Citracal product contained not only calcium citrate, but also calcium carbonate. Citracal Plus Bone Density Builder actually contains more calcium carbonate per tablet than calcium citrate (240 mg vs. 60 mg). Another Citracal product, Citracal Plus Heart Health, also contains more calcium carbonate than calcium citrate. Many clinicians prefer calcium citrate because it can be taken with or without food, while calcium carbonate must be taken with food for optimal absorption. Other familiar over-the-counter (OTC) names also contain...
Over-the-counter Omeprazole (Prilosec OTC)
The Medical Letter on Drugs and Therapeutics • Aug 04, 2003 (Issue 1162)
recently approved the proton pump inhibitor omeprazole magnesium (Prilosec
OTC) for over-the-counter use ...
The FDA recently approved the proton pump inhibitor omeprazole magnesium (Prilosec OTC) for over-the-counter use for treatment of frequent heartburn. It will be marketed in late September or early October. Five proton pump inhibitors, including omeprazole, are available by prescription in the US (Medical Letter 2001; 43:36).
Cisapride for Nocturnal Heartburn
The Medical Letter on Drugs and Therapeutics • Feb 04, 1994 (Issue 915)
ingredients such as aluminum hydroxide, magnesium carbonate, magnesium hydroxide, calcium carbonate, potassium ...
Cisapride (Propulsid - Janssen), a piperidinyl benzamide prokinetic drug, is now available in the USA for symptomatic relief of nocturnal heartburn due to gastroesophageal reflux disease. In Canada, cisapride is also marketed for treatment of gastroparesis.
Riociguat (Adempas) for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 03, 2014 (Issue 1437)
to nonsmokers. Antacids
such as aluminum hydroxide/magnesium hydroxide reduce
absorption of riociguat.
DOSAGE ...
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension
(CTEPH) following surgery or when surgery is not an
option. It is the first drug to be approved for treatment
of CTEPH.
Nizatidine (Axid)
The Medical Letter on Drugs and Therapeutics • Aug 12, 1988 (Issue 772)
containing aluminum and magnesium hydroxide with simethicone (Gelusil) decreased
absorption by about 10 ...
Nizatidine (Axid - Lilly), a new H2-receptor antagonist similar to cimetidine (Tagamet), ranitidine (Zantac) and famotidine (Pepcid), was recently approved by the US Food and Drug Administration for treatment of active duodenal ulcer and for maintenance therapy after healing. Cimetidine, ranitidine and famotidine are also approved for treatment of pathological hypersecretory conditions such as Zollinger- Ellison syndrome; cimetidine is approved in addition for treatment of gastric ulcers.
Rosuvastatin - a New Lipid-lowering Drug
The Medical Letter on Drugs and Therapeutics • Oct 13, 2003 (Issue 1167)
(International
Normalized Ratio). Antacids containing aluminum and magnesium hydroxide decrease absorption ...
Rosuvastatin (Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol levels. Rosuvastatin, like other statins, inhibits the enzyme that catalyzes the rate-limiting step in cholesterol synthesis, but it is claimed to be more potent than the others. All of these drugs must be taken indefinitely; if they are discontinued, lipid levels return to baseline.
Cerivastatin for Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • Jan 16, 1998 (Issue 1018)
of magnesium-aluminum hydroxide (Maalox, and others), cimetidine
(Tagamet, and others), digoxin (Lanoxin ...
Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic acid.
Comparison Table: Some Oral Antiseizure Medications (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
containing aluminum or
magnesium hydroxide
No adequate studies in
pregnant women; developmental
toxicity ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40 doi:10.58347/tml.2024.1708b | Show Introduction Hide Introduction
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
— Antacids containing aluminum, magnesium,
and/or calcium carbonate can provide rapid
but transient relief ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.
Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
taken with magnesium or aluminum hydroxide; gabapentin should be taken 2 hours after antacids containing ...
When used for the appropriate seizure type,
antiseizure medications (ASMs) are roughly
equivalent in efficacy. In addition to the seizure type,
the choice of drug is usually based on factors such
as ease of use, spectrum of activity, adverse effects,
interactions with other drugs, presence of comorbid
conditions, suitability for elderly persons and those
with childbearing potential, and cost. Treatment
should begin with a single drug, increasing the
dosage gradually until seizures are controlled or
adverse effects become unacceptable. If seizures
persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8 doi:10.58347/tml.2024.1708a | Show Introduction Hide Introduction